RYTM Logo

Rhythm Pharmaceuticals, Inc. (RYTM) 

NASDAQ
Market Cap
$3.65B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
701 of 774
Rank in Industry
386 of 432

Largest Insider Buys in Sector

RYTM Stock Price History Chart

RYTM Stock Performance

About Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC …

Insider Activity of Rhythm Pharmaceuticals, Inc.

Over the last 12 months, insiders at Rhythm Pharmaceuticals, Inc. have bought $0 and sold $28.59M worth of Rhythm Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Rhythm Pharmaceuticals, Inc. have bought $201,713 and sold $18.91M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 10,000 shares for transaction amount of $201,713 was made by Meeker David P (President and CEO) on 2021‑03‑30.

List of Insider Buy and Sell Transactions, Rhythm Pharmaceuticals, Inc.

2024-11-11SaleEVP, Head of North America
66,861
0.11%
$66.33$4.43M-8.94%
2024-11-11SaleChief Technical Officer
13,281
0.0219%
$66.44$882,341-8.94%
2024-11-07SaleChief Human Resources Officer
4,688
0.0079%
$65.00$304,720-2.87%
2024-11-06SaleChief Human Resources Officer
4,687
0.0073%
$60.00$281,220+2.00%
2024-09-17Saledirector
31,751
0.0512%
$52.40$1.66M-4.00%
2024-09-10Saledirector
17,501
0.029%
$49.65$868,923+3.93%
2024-09-09SaleChief Human Resources Officer
4,099
0.0066%
$50.03$205,062+0.69%
2024-09-09Saledirector
3,199
0.0052%
$50.04$160,068+0.69%
2024-09-09Saledirector
37,241
0.0607%
$50.45$1.88M+0.69%
2024-08-26SaleChief Human Resources Officer
3,200
0.0052%
$50.01$160,018+0.43%
2024-08-26Saledirector
4,300
0.007%
$50.01$215,029+0.43%
2024-08-26Saledirector
14,508
0.0237%
$50.01$725,526+0.43%
2024-08-12Saledirector
10,000
0.0165%
$44.65$446,462+11.79%
2024-08-09SaleChief Human Resources Officer
49,006
0.08%
$45.15$2.21M+9.66%
2024-07-29SaleChief Human Resources Officer
1,395
0.0023%
$49.06$68,439+1.62%
2024-07-16SaleChief Technical Officer
10,468
0.0228%
$53.00$554,817-8.07%
2024-07-12SaleChief Technical Officer
5,313
0.0109%
$50.01$265,7250.00%
2024-05-09SaleChief Technical Officer
3,984
0.0065%
$38.47$153,259+23.11%
2024-04-02SaleCorporate Controller & CAO
368
0.0006%
$41.76$15,368+11.06%
2024-03-21SaleChief Technical Officer
18,235
0.0301%
$40.34$735,600+8.55%

Insider Historical Profitability

5.95%
Meeker David PPresident and CEO
174605
0.2841%
$59.3122<0.0001%
BARRIS PETER J10 percent owner
4909956
7.9892%
$59.3110+9.57%
BARRETT M JAMES10 percent owner
4909956
7.9892%
$59.3110+9.57%
MOTT DAVID M10 percent owner
4909956
7.9892%
$59.3110+9.57%
KERINS PATRICK J10 percent owner
4909956
7.9892%
$59.3110+9.57%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
PRIMECAP Management Co$335.7M12.717.75M-3.79%-$13.22M0.25
BlackRock$282.93M10.716.53M+2.8%+$7.71M0.01
Baker Bros Advisors LP$277.24M10.496.4M0%+$01.99
RA Capital Management, L.P.$230.97M8.745.33M0%+$00.23
Goldman Sachs$221.49M8.385.11M+1.26%+$2.76M0.04
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.